Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.414 5-Year IF: 3.324 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v28.i1.10
pages 1-45

Engineered PLGA Nanoparticles: An Emerging Delivery Tool in Cancer Therapeutics

Amit K. Jain
Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar (Mohali), Punjab, India
Manasmita Das
Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar (Mohali), Punjab, India
Nitin K. Swarnakar
Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar (Mohali), Punjab, India
Sanyog Jain
Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar (Mohali), Punjab, India

ABSTRACT

Nanocarriers formulated with the US Food and Drug Administration-approved biocompatible and biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) are being widely explored for the controlled delivery of therapeutic drugs, proteins, peptides, oligonucleotides, and genes. Surface functionalization of PLGA nanoparticles has paved the way to a variety of engineered PLGA-based nanocarriers, which, depending on reticular requirements, can demonstrate a wide variety of combined properties and functions such as prolonged residence time in blood circulation, enhanced oral bioavailability, site-specific drug delivery, and tailored release characteristics. The present review highlights the recent leaps in PLGA-based nanotechnology with a particular focus on cancer therapeutics. Starting with a brief introduction to cancer nanotechnology, we then discuss developmental aspects and the in vitro and in vivo efficacy of PLGA-based nanocarriers in terms of targeted drug or gene delivery. The main objective of this review is to convey information about the state of art and to critically address the limitations and the need for further progress and clinical developments in this emerging technology.


Articles with similar content:

Overview on Therapeutic Applications of Microparticulate Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 4
Swarna Bale, Mandip Singh, A. Shiva Shankar Reddy, Amit Khurana, Chandraiah Godugu
Lipid Nanocarriers: Influence of Lipids on Product Development and Pharmacokinetics
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 4
Lav Keshri, Mayank Shah, Kamla Pathak
Peptide and Protein Delivery Using New Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 4
Ashish Jain, Satish Shilpi, Pooja Hurkat, Aviral Jain, Arvind Gulbake, Sanjay Kumar Jain
The effective role of hydroxyapatite-based composites in anti-cancer drug delivery systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 1
Samaneh Saber-Samandari
Tiny Technology Proves Big: A Challenge at Engineering, Medicine and Pharmaceutical Sciences Interface
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 1
Aswini K. Mohapatra, Anjan K. Mahapatra, P. N. Murthy, Supriya Samoju